SG Americas Securities LLC Acquires New Position in Achillion Pharmaceuticals, Inc. (ACHN)

Share on StockTwits

SG Americas Securities LLC acquired a new position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) during the fourth quarter, Holdings Channel reports. The fund acquired 46,216 shares of the biopharmaceutical company’s stock, valued at approximately $73,000.

Other institutional investors have also bought and sold shares of the company. Meeder Asset Management Inc. boosted its stake in Achillion Pharmaceuticals by 107.3% in the fourth quarter. Meeder Asset Management Inc. now owns 26,476 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 13,706 shares in the last quarter. Logan Capital Management Inc. acquired a new position in Achillion Pharmaceuticals in the third quarter worth $166,000. MetLife Investment Advisors LLC boosted its stake in Achillion Pharmaceuticals by 81.0% in the third quarter. MetLife Investment Advisors LLC now owns 101,528 shares of the biopharmaceutical company’s stock worth $374,000 after purchasing an additional 45,425 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Achillion Pharmaceuticals by 20.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,757 shares of the biopharmaceutical company’s stock worth $452,000 after purchasing an additional 20,450 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in Achillion Pharmaceuticals by 42.5% in the fourth quarter. Rhumbline Advisers now owns 198,304 shares of the biopharmaceutical company’s stock worth $315,000 after purchasing an additional 59,114 shares in the last quarter. 76.73% of the stock is currently owned by institutional investors.

ACHN has been the topic of a number of recent analyst reports. BidaskClub raised Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, February 22nd. ValuEngine raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Zacks Investment Research raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, William Blair restated an “outperform” rating on shares of Achillion Pharmaceuticals in a research report on Thursday, March 7th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $4.50.

ACHN stock opened at $2.92 on Wednesday. The firm has a market cap of $392.28 million, a PE ratio of -4.71 and a beta of 2.39. Achillion Pharmaceuticals, Inc. has a twelve month low of $1.29 and a twelve month high of $4.34.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. On average, research analysts forecast that Achillion Pharmaceuticals, Inc. will post -0.52 EPS for the current year.

WARNING: “SG Americas Securities LLC Acquires New Position in Achillion Pharmaceuticals, Inc. (ACHN)” was originally posted by Highlight Press and is the sole property of of Highlight Press. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://highlightpress.com/2019/03/13/sg-americas-securities-llc-acquires-new-position-in-achillion-pharmaceuticals-inc-achn.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Featured Story: Trading Strategy Examples and Plans

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply